Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Mayo Clinic
OHSU Knight Cancer Institute
University of California, Davis
City of Hope Medical Center
Maastricht University Medical Center
University of Pittsburgh
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Institut de Cancérologie de Lorraine
West China Hospital
University of Pittsburgh
M.D. Anderson Cancer Center
NuCana plc
Providence Health & Services
Oslo University Hospital
University of Palermo
Thomas Jefferson University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Maastricht University Medical Center
Providence Health & Services
The Methodist Hospital Research Institute
UNICANCER
University of Pittsburgh
University of California, San Francisco
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Maastricht University Medical Center
Providence Health & Services
Providence Health & Services
Herlev Hospital
Institut du Cancer de Montpellier - Val d'Aurelle
Ludwig Institute for Cancer Research
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Case Comprehensive Cancer Center